No more noise: uncertainty around the regulator is fading
This looks positive for $Hims & Hers Health Inc.(HIMS)$
HIMS came under pressure after Marty Makary’s FDA crackdown on compounded GLP-1s. The February 2026 announcement targeted mass-marketed compounded versions sold by firms like Hims over safety and quality concerns, triggering a sharp selloff and raising pressure on the company’s core telehealth and compounding business model.
With his removal, the market may start pricing in the possibility of lighter enforcement on compounding and telehealth services — an area that remains central to HIMS’ competitive positioning against and . Near term, sentiment could turn more bullish if investors believe regulatory risks may ease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- Ah_Meng·05-16TOPSounds bad for drug companies in general to have less oversight and decrease valuations in their patents… yup, good for copycats like HIMS [Facepalm]LikeReport